Hua Medicine
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A commercial-stage company launching a novel diabetes drug in China.
Metabolic
Technology Platform
Focused expertise in developing glucokinase activators, a novel class of small molecules for restoring glucose homeostasis in diabetes.
Opportunities
First-mover advantage with a novel mechanism of action in the world's largest diabetes market, offering a differentiated treatment option.
Risk Factors
Commercial execution risk in a price-sensitive market and the challenge of changing physician prescribing habits away from entrenched therapies.
Competitive Landscape
Competes in the enormous but crowded diabetes market against inexpensive generics and highly effective newer drug classes with strong cardiovascular benefits.